Cytobiologics Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 1.21 Cr
as on 17-12-2024
- Company Age 3 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 22.91 Cr
as on 17-12-2024
- Satisfied Charges ₹ 18.00 Cr
as on 17-12-2024
- Revenue 8000.43%
(FY 2023)
- Profit 4619.49%
(FY 2023)
- Ebitda 9273.57%
(FY 2023)
- Net Worth 2377.34%
(FY 2023)
- Total Assets 47.83%
(FY 2023)
About Cytobiologics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.21 Cr.
The company currently has active open charges totaling ₹22.91 Cr. The company has closed loans amounting to ₹18.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jeevan Lekkala, Gopi Lekkala, and Rajesh Tummuru serve as directors at the Company.
- CIN/LLPIN
U24290TG2021PTC151278
- Company No.
151278
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 May 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Cytobiologics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jeevan Lekkala  | Director | 30-Aug-2022 | Current |
| Gopi Lekkala | Director | 10-May-2021 | Current |
| Rajesh Tummuru | Director | 10-May-2021 | Current |
Financial Performance of Cytobiologics.
Cytobiologics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 8000.43% increase. The company also saw a substantial improvement in profitability, with a 4619.49% increase in profit. The company's net worth Soared by an impressive increase of 2377.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cytobiologics?
Unlock access to Cytobiologics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Lekcon Infrastructure Private LimitedActive 15 years 9 monthsJeevan Lekkala and Gopi Lekkala are mutual person
Lekcon Realty & Developers LlpActive 1 year 1 monthJeevan Lekkala and Gopi Lekkala are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 22 Jul 2024 | ₹1.16 Cr | Open |
Others Creation Date: 29 Dec 2023 | ₹21.75 Cr | Open |
Others Creation Date: 03 Dec 2022 | ₹3.00 Cr | Satisfied |
How Many Employees Work at Cytobiologics?
Cytobiologics has a workforce of 139 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cytobiologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cytobiologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
